Literature DB >> 3643712

Individual reaction steps in the release of kallidin from kininogen by tissue kallikrein.

F Fiedler, H Hinz, F Lottspeich.   

Abstract

At low pH values (around 6), porcine pancreatic beta-kallikrein B attacks at first the C-terminal ARg bond of the kinin moiety in bovine HMW kininogen. Arg-cleaved kininogen accumulates as an intermediate in the solution. Kallidin is released by cleavage of the aminoterminal Met-Lys bond in a second step. At pH values between 7.6 and 9, however, Arg-cleaved kininogen does not occur as a free intermediate. The participation as a (free, not only enzyme-bound) intermediate of Arg-cleaved kininogen in a short-lived especially reactive conformation or of Met-cleaved kininogen is also unlikely. Probably, both the Met and the Arg bonds are hydrolyzed in one enzyme-substrate complex which does not dissociate between these two events. Kinetic constants for the release of kallidin from native single-chain HMW kininogen and from Arg-cleaved kininogen (even if this Arg residue is removed) remarkably have the same values. Evidently, the rate of the reaction is determined by steps leading to the hydrolysis of the Met bond. As the state of the C-terminal Arg residue has no influence, the efficient cleavage of the Met bond by tissue kallikrein is probably not due to some strain in the kininogen molecule in the region of this bond. As modification of Arg residues of kininogen prevents cleavage also of the Met bond, some Arg residue(s) appear(s) to play a crucial role in this process. kcat/Km (1.4 x 10(6) M-1 sex-1 at pH 9, 25 degrees C) is very high for a proteolytic reaction, mainly because of the low value of Km (0.6 microM).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3643712     DOI: 10.1007/978-1-4684-5143-6_39

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.

Authors:  B A Katz; B Liu; M Barnes; E B Springman
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

2.  Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites.

Authors:  F C Portaro; M H Cezari; M A Juliano; L Juliano; A R Walmsley; E S Prado
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

3.  Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.

Authors:  D C Pimenta; J Chao; L Chao; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

4.  Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments.

Authors:  E Del Nery; J R Chagas; M A Juliano; E S Prado; L Juliano
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.